COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX:CLN) today reported that it had received positive indications from its collaborators that docetaxel entrapped in its temperature sensitive liposome demonstrates improved anti-tumor effect in vivo. Mice with xenographic lung cell tumors were treated with free docetaxel, non temperature sensitive liposomes containing docetaxel and temperature sensitive liposomes containing docetaxel in the presence of heat. Following treatment the reduction in tumor volume was measured. Results indicate that the reduction generated by the heat activated liposomal formulation was statistically superior to both the free docetaxel and the non temperature sensitive liposome formulation. Based on these results, the company has expanded its research efforts in this area including confirmational studies of the initial results.
